Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: No further effect of vitamin E

Circulation

Volumn 106, Issue 20, 2002, Pages 2543-2549

  De Caterina, Raffaele ^a   Cipollone, Francesco ^a   Filardo, Francesca Paola ^a   Zimarino, Marco ^a   Bernini, Walter ^a   Lazzerini, Guido ^a   Bucciarelli, Tonino ^a   Falco, Angela ^a   Marchesani, Paola ^a   Muraro, Raffaella ^a   Mezzetti, Andrea ^a   Ciabattoni, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherosclerosis; Lipids; Peroxidation; Pharmacology; Stress

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 8 ISOPROSTAGLANDIN F2 ALPHA; ALPHA TOCOPHEROL; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LINEAR REGRESSION ANALYSIS; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; VITAMIN BLOOD LEVEL;

ANTIOXIDANTS; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DINOPROST; DRUG THERAPY, COMBINATION; F2-ISOPROSTANES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PATIENT COMPLIANCE; SIMVASTATIN; VITAMIN E;

EID: 0037069383     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000038500.43292.D7     Document Type: Article

References (39)

1. Witztum JL. The role of monocytes and oxidized LDL in atherosclerosis. In: Leaf A, Weber P. eds. Atherosclerosis Reviews: Prevention and Noninvasive Therapy of Atherosclerosis. New York, NY: Raven Press: 1990:59-69.
2. Libby P. Current concepts on the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
3. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-455.
4. Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alphatocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000;20:230-235.
5. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.
6. The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet. 2001;357:89-95.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
9. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
10. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
11. West of Scotland Coronary Prevention Study Group. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996;348:1339-1342.
12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and woman with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
13. Lavy A, Brook G, Dankner G, et al. Enhanced in vitro oxidation of plasma lipoprotein derived from hypercholesterolemic patients. Metabolism. 1991;40:794-799.
14. Cominacini L, Pastorino A, Garbin U, et al. The susceptibility of lowdensity lipoproteins to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition. 1994;10:527-531.
15. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 1997;128:11-18.
16. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
17. Wassmann S, Laufs U, Müller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305.
18. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem. 1999;274:24441-24444.
19. Rokach J, Khanapure SP, Hwang SW, et al. Nomenclature of isoprostanes: A proposal. Prostaglandins. 1997;54:853-873.
20. Davì G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224-229.
21. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-1203.
22. Reilly M, Delanty N, Lawson JA, et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94:19-25.
23. Davì G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-epiprostaglandin F2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230-3235.
24. Reilly MP, Praticò D, Delanty N, et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998;98:2822-2828.
25. Patrignani P, Panara MR, Tacconelli S, et al. Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation. 2000;102:539-545.
26. Lee BL, Chua SC, Ong HY, et al. High-performance liquid chromatographic method for routine determination of vitamins A and E and β-carotene in plasma. J Chromatogr. 1992;581:41-47.
27. Traber MG, Jialal I. Measurement of lipid-soluble vitamins: Further adjustment needed? Lancet. 2000;355:2013-2014.
28. Wang Z, Ciabattoni G, Creminon C, et al. Immunological characterization of urinary 8-epi-prostaglandin F2α excretion in man. J Pharmacol Exp Ther. 1995;275:94-100.
29. Holvoet P, Perez G, Bernar H, et al. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation. J Clin Invest. 1994;93:89-98.
30. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487-1494.
31. Adult Treatment Panel III. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
32. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirininsensitive thromboxane biosynthesis in severe unstable angina. Circulation. 2000;102:1007-1013.
33. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2001;21:844-848.
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:23-33.
35. Dimitrov NV, Meyer C, Gilliland D, et al. Plasma tocopherol concentrations in response to supplemental vitamin E. Am J Clin Nutr. 1991;53:723-729.
36. Brigelius-Flohé R, Traber MG. Vitamin E: Function and metabolism. FASEB J. 1999;13:1145-1155.
37. Traber MG, Rader D, Acuff RV, et al. Vitamin E dose-response studies in humans with use of deuterated RRR-α-tocopherol. Am J Clin Nutr. 1998;68:847-853.
38. Violi F, Micheletta F, Iuliano L. Vitamin E, atherosclerosis and thrombosis. Thromb Haemost. 2001;85:766-770.
39. Stephens NG, Parson A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet. 1996;347:781-786.